Re: Potential Cholesterol-Lowering Effect of Artichoke Leaf Extract
Wider B, Pittler MH, Thompson-Coon J, Ernst E.
Artichoke leaf extract for treating hypercholesterolemia. Cochrane Database Syst Rev. 2009;4:CD000335. DOI:
10.1002/14651858.CD003335.pub2.
The World
Health Organization estimates that approximately 8% of all disease in developed
countries is caused by elevated total cholesterol levels and that more than 60%
of coronary heart disease cases are due to total cholesterol levels that exceed
3.8 mmol/L. According to National Cholesterol Education Program guidelines,
approximately 30% of Americans have "undesirably high serum cholesterol levels."
Standard treatment options for hypercholesterolemia include the use of statins;
however, statin use is associated with adverse effects, such as carcinogenicity
and liver damage. Therefore, treatment options without harmful side effects are
desirable.
Artichoke (Cynara scolymus) leaf extract (ALE),
which contains 1% caffeic acid derivatives, 1% flavonoids, and sesquiterpenes,
has been proposed as one such treatment option. ALE has traditionally been used
medicinally as a diuretic, a choleretic, and for liver problems (e.g.,
jaundice). In animal studies, ALE was shown to decrease plasma cholesterol and
triglyceride levels and to prevent the development of atherosclerosis, likely
because of its antioxidative effects. The cholesterol-lowering effects of ALE
have also been observed in several case reports and uncontrolled studies in
humans; however, the results of randomized controlled trials are needed to
establish a cause-effect relationship. Thus, the objective of the present study
was to review the results of randomized controlled trials (RCTs) that evaluated
the cholesterol-lowering effects of ALE in hypercholesterolemic patients.
A literature
search of the Cochrane Register of Controlled Trials, MEDLINE, EMBASE, AMED,
and CINAHL through 2008 and of CISCOM through 2001 was conducted to identify RCTs
that evaluated the use of oral preparations containing ALE as the only
component in patients with hypercholesterolemia [defined as a total cholesterol
level of at least 5.17 mmol/L (200 mg/dL)] in comparison with a placebo or
reference medication. In addition, published and unpublished information was
solicited from manufacturers of artichoke preparations and experts on the
subject, and the bibliographies of the articles retrieved were searched for
pertinent trials. Three double-blind RCTs met the inclusion criteria and were
included in this review.1-3 Information on the methods used, patient
characteristics, interventions, and results were systematically extracted from
these articles. The primary outcomes of interest were reductions in total
cholesterol, low-density-lipoprotein (LDL)-cholesterol,
high-density-lipoprotein (HDL)-cholesterol, and triglyceride levels. The
methodologic quality of the trials was evaluated by two reviewers, and any disagreements
were resolved through discussion.
In the
study by Bundy et al,1 75 men and women in the United Kingdom, most of whom were
older than 50 years, received either 1280 mg ALE or placebo daily for 12 weeks.
The total cholesterol level decreased by 42% in the ALE group but increased in
the placebo group; the difference in change between groups was significantly
different (P = 0.025). No significant differences in the changes in HDL, LDL,
and triacylglycerol levels were observed.
In the
study by Englisch et al,2 which was conducted in Russia, 143 women aged 18-70 years
received either 1800 mg ALE or placebo daily for 6 weeks. The total cholesterol
level decreased by 18.5% in the ALE group and by 8.6% in the placebo group; the
difference between groups was significant (P < 0.00001). The LDL-cholesterol
level also decreased significantly more in the ALE group than in the placebo
group (P < 0.00001); however, HDL and triacylglycerol levels were not
significantly different between groups.
In the
study by Petrowicz et al (abstract),3 which was conducted in Germany,
44 healthy men and women aged 20-49 years received either 1920 mg ALE or
placebo daily for 12 weeks. No significant effects of ALE were observed on
serum HDL, LDL, total, or triacylglycerol levels in the total sample. However,
total cholesterol levels decreased significantly in the subjects with an
initial total cholesterol level of 230 mg/dL compared with the placebo group (P
= 0.015).
All three studies
reviewed were of "adequate methodological quality." The evidence from
these three studies "suggests a modest positive effect of ALE on total and
LDL cholesterol levels." However, the authors conclude that the evidence
is "not compelling enough to recommend ALE as a treatment option for
hypercholesterolemia." The limited data on safety suggest that the
short-term use of ALE is associated with only mild and transient infrequent
adverse events.
—Brenda Milot, ELS
References
1Bundy R, Walker AF, Middleton RW, Wallis
C, Simpson HC. Artichoke leaf extract (Cynara
scolymus) reduces plasma cholesterol in otherwise healthy
hypercholesterolemic adults: a randomized, double
2Englisch W, Beckers C, Unkauf M, Ruepp M,
Zinserling V. Efficacy of artichoke dry extract in patients with
hyperlipoproteinemia. Arzneimittel-Forschung. 2000;50:260-265.
3Petrowicz O, Gebhardt R,
Donner M, Schwandt M, Kraft K. Effects of artichoke leaf extract (ALE) on
lipoprotein metabolism in vitro and in vivo. Atherosclerosis. 1997;129:147.